FDA-approved GLP-1 medications for weight management (Wegovy, Zepbound, Saxenda) require: BMI ≥30 (obesity class I or higher), OR BMI ≥27 (overweight) with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea. GLP-1s approved for type 2 diabetes (Ozempic, Mounjaro, Rybelsus) do not have a BMI requirement for that indication.
BMI is a widely used screening tool but has limitations. It doesn't account for muscle mass, bone density, fat distribution, age, sex, or ethnicity. Athletes may have high BMI due to muscle, while someone with a "normal" BMI can have unhealthy fat distribution. The FDA uses BMI as one criterion for GLP-1 eligibility, but clinical assessment by a provider considers the full picture.
For the weight management indication, it is very difficult to get coverage or even a prescription for most GLP-1s with BMI under 27, as FDA approval requires BMI ≥27. However, GLP-1s for type 2 diabetes (Ozempic, Mounjaro, Rybelsus) may be prescribed regardless of BMI if you have T2D. Off-label use at lower BMIs exists but is less common and generally not covered by insurance.
FDA-recognized weight-related comorbidities include: type 2 diabetes (or prediabetes), hypertension, dyslipidemia (high cholesterol/triglycerides), obstructive sleep apnea (OSA), cardiovascular disease, and polycystic ovarian syndrome (PCOS). These conditions must be diagnosed by a healthcare provider to count toward eligibility.
Yes — clinical evidence shows GLP-1 medications are effective for weight loss across the BMI spectrum. Several trials have included patients with BMI 27–30 who experienced similar percentage weight loss. However, insurance coverage and on-label prescribing typically require BMI ≥30 or ≥27 with comorbidity.
Obesity is classified into three classes: Class I (BMI 30–34.9), Class II (BMI 35–39.9), and Class III or "severe obesity" (BMI ≥40, formerly called "morbid obesity"). All three classes qualify for GLP-1 weight management therapy. Patients with higher obesity classes may lose more absolute weight (though similar percentage) on GLP-1 therapy.
BMI is calculated as weight (kg) divided by height² (m²). In US customary units: BMI = (weight in lbs × 703) / (height in inches)². For example, a person 5'9" (69 inches) weighing 200 lbs has a BMI of (200 × 703) / (69²) = 140,600 / 4,761 ≈ 29.5 (overweight).
BMI is one eligibility criterion, but a complete medical evaluation is required before any prescription. Your provider will review your medical history, current conditions, medications, contraindications (e.g., personal/family history of medullary thyroid cancer, pancreatitis, MEN-2 syndrome), and overall health goals. Meeting the BMI criterion is necessary but not sufficient on its own.
The standard BMI categories are: Underweight <18.5, Normal 18.5–24.9, Overweight 25.0–29.9, Obese ≥30. A "healthy" BMI is generally considered 18.5–24.9, though this is population-level data. Asian populations may have health risks at lower BMIs, and the definition of "healthy" varies by individual factors.
Yes, physicians can legally prescribe any medication off-label. Some providers prescribe GLP-1s for patients with BMI 25–30 who have metabolic issues or struggle with weight. However, insurance typically won't cover these prescriptions without meeting the BMI threshold, and out-of-pocket costs can be significant ($1,000+/month at list price).
Check Your Eligibility with a Real Provider
BMI is just one factor. A licensed telehealth provider can do a complete evaluation and prescribe GLP-1 therapy if appropriate.